Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease

Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H(+)/K(+)-ATPase blocker that is approved in Japan for treatment of GERD. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabuchi, Maiko, Minami, Hitomi, Akazawa, Yuko, Ashida, Miwa, Hara, Toshihide, Ichinose, Kunihiro, Kitayama, Moto, Hashiguchi, Keiichi, Matsushima, Kayoko, Yamaguchi, Naoyuki, Takeshima, Fuminao, Kondo, Hisayoshi, Kawakami, Atsushi, Nakao, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780750/
https://www.ncbi.nlm.nih.gov/pubmed/33408859
http://dx.doi.org/10.3892/br.2020.1401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780750/
https://www.ncbi.nlm.nih.gov/pubmed/33408859
http://dx.doi.org/10.3892/br.2020.1401

Ejemplares similares